CEO Sell resigns; agilon posts $104M Q2 net loss, suspends 2025 guidance

agilon health, inc.

Steven Sell resigned as CEO/President and Board director effective July 29; Board reduced to seven directors.
Executive Chairman Ron Williams appointed; Office of the Chairman formed to oversee interim operations.
Q2 total revenue $1.39B (-6% YoY); net loss $104M vs $31M loss in Q2 2024.
Medical margin negative $53M vs positive $106M; adjusted EBITDA loss $83M vs $3M loss.
Full-year 2025 guidance suspended due to leadership change and market headwinds.

item 2.02 item 5.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

agilon health, inc.: Amended and restated the bylaws to adopt amendments relating to officer positions and technical updates reflecting Delaware law changes (effective 2025-07-29).

Change: bylaw amendment
Effective: 2025-07-29

Exact text from the filing

On July 29, 2025, the Board amended and restated the by-laws of the Company (as amended, the “Amended and Restated By-laws”).

View on SEC.gov

Browse all governance changes →

agilon health, inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-037426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.